<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lock therapy for treatment and prevention of intravascular non-hemodialysis catheter-related infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lock therapy for treatment and prevention of intravascular non-hemodialysis catheter-related infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lock therapy for treatment and prevention of intravascular non-hemodialysis catheter-related infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heather L Girand, PharmD, BCPPS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Chase McNeil, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H50341274"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Catheter-related bloodstream infection (CRBSI) is a significant cause of morbidity and mortality. Issues related to the epidemiology, microbiology, clinical manifestations, diagnosis, and treatment of CRBSI are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/z/d/html/3813.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a>.)</p><p>Types of central venous catheters (CVCs) include nontunneled catheters, tunneled catheters, and subcutaneous ports  (<a class="graphic graphic_figure graphicRef95494" href="/z/d/graphic/95494.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">"Central venous access in adults: General principles"</a>.)</p><p>For circumstances in which catheter or port removal is not feasible and salvage is attempted (eg, retention of the catheter with administration of antimicrobial therapy), systemic antimicrobial therapy is used in conjunction with antibiotic lock therapy (ALT) [<a href="#rid1">1</a>]. ALT refers to instillation of a concentrated antibiotic solution into the catheter lumen and allowing the solution to dwell in the catheter for a set period of time with the goal of achieving a sustained drug level high enough to kill bacteria within the biofilm of the catheter. </p><p>Issues related to use of antimicrobial locks for adjunctive treatment of CRBSI in patients with CVCs (apart from hemodialysis catheters) are discussed here, as are issues related to use of antimicrobial and ethanol locks for prevention of CRBSI. </p><p>Issues related to ALT in the setting of hemodialysis catheter infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a> and  <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a>.)</p><p>Other issues related to prevention of CRBSI are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a> and  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.)</p><p class="headingAnchor" id="H50341281"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>Catheter-related bloodstream infection (CRBSI) is associated with the development of biofilm on the catheter luminal surface; a biofilm is an aggregate of microorganisms encased in a matrix of self-produced exopolysaccharides that in turn adhere tightly to surfaces. </p><p>Antibiotic lock therapy (ALT) provides a concentrated antibiotic solution into the catheter lumen to achieve a drug level high enough to kill bacteria within the biofilm of the catheter. </p><p>Bacteria in a biofilm can be difficult to eradicate with systemic antibiotic administration [<a href="#rid2">2-5</a>]. Antibiotic concentrations must be 100- to 1000-fold higher to kill sessile bacteria (those adhered to a surface) within a biofilm than to kill planktonic bacteria (those floating as single cells) [<a href="#rid4">4,6</a>]. In addition, antibiotic penetration into biofilm is variable and depends on factors such as biofilm composition and antibiotic physical and biochemical properties [<a href="#rid7">7</a>]. </p><p>Anticoagulants may be beneficial in ALT for treatment of CRBSI by interfering with fibrin formation and allowing increased antibiotic penetration into microbial biofilms [<a href="#rid8">8,9</a>]. However, data from other studies suggest that heparin may stimulate <em>Staphylococcus aureus</em> biofilm formation, although this finding is not universally accepted [<a href="#rid10">10-14</a>]. </p><p class="headingAnchor" id="H2951809627"><span class="h1">LOCK USE FOR ADJUNCTIVE CRBSI TREATMENT</span><span class="headingEndMark"> — </span>For circumstances in which catheter salvage is attempted (eg, retention of the catheter with administration of antimicrobial therapy), management includes antibiotic lock therapy (ALT) in conjunction with systemic antimicrobial therapy [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Catheter salvaged'</a>.)</p><p class="headingAnchor" id="H13928254"><span class="h2">Indications</span><span class="headingEndMark"> — </span>In general, ALT is used as adjunctive therapy together with systemic antibiotics for treatment of catheter-related bloodstream infection (CRBSI) in the setting of catheter salvage. Candidates for catheter salvage include patients with a long-term intravascular device (&gt;14 days) who are hemodynamically stable with CRBSI due to a pathogen of relatively low virulence (such as coagulase-negative staphylococci or drug-susceptible Enterobacteriaceae) in the absence of complications (eg, septic thrombophlebitis, endocarditis, or metastatic musculoskeletal infection). </p><p>Catheter salvage should not be attempted in patients with a condition warranting catheter removal  (<a class="graphic graphic_table graphicRef122402" href="/z/d/graphic/122402.html" rel="external">table 1</a>). In addition, catheter salvage, even with ALT, should not be attempted in the setting of persistent or relapsed CRBSI following appropriate antimicrobial therapy. Issues related to deciding between catheter salvage and catheter removal are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Selecting a catheter management strategy'</a>.)</p><p>In the setting of bloodstream infection (BSI) associated with a subcutaneous port, indications for adjunctive ALT are the same as the indications for adjunctive ALT in the setting of other CRBSI [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H3750280219"><span class="h2">Antibiotic lock solutions</span></p><p class="headingAnchor" id="H112483117"><span class="h3">Selection</span><span class="headingEndMark"> — </span>An "antibiotic lock" is a highly concentrated antibiotic solution, often combined with an anticoagulant such as heparin, administered in a volume sufficient to fill and dwell in the catheter lumen when the catheter is not in use. When catheters are needed for intravenous access, the antibiotic lock solution must be withdrawn to avoid systemic exposure to toxic high concentrations of antibiotics and/or anticoagulants [<a href="#rid17">17,18</a>]. (See <a class="local">'Preparation, instillation, and dwell time'</a> below.) </p><p>Ideally, the antimicrobial lock solution should be chemically stable, compatible with anticoagulants or other additives (if applicable), active against the organisms in the biofilm, have a low risk of adverse events and toxicity, and a low potential for inducing resistance. </p><p>The optimal approach to antibiotic selection or dosing for ALT is uncertain; thus far, there have been no rigorous studies comparing the efficacy and safety of various types of antibiotic lock solutions. Antibiotic selection for ALT should be guided by the antimicrobial susceptibility of the infecting organism, the available dwell time between venous access, and individual patient factors. Commonly used antibiotics that are compatible with heparin and remain active and stable for prolonged periods include <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>. These and other ALT solutions are summarized in the table  (<a class="graphic graphic_table graphicRef122410" href="/z/d/graphic/122410.html" rel="external">table 2</a>). Alternative agents not listed in the preceding table have been used for ALT, but we do not recommend these agents for routine use [<a href="#rid1">1,19-30</a>]. (See <a class="local">'Limitations of other lock types'</a> below.)</p><p>In vitro studies have consistently shown that high antibiotic concentrations are required to kill bacteria within a biofilm; thus antibiotic concentrations in lock solutions should exceed the minimum inhibitory concentration of the known or suspected infecting organism by 1000-fold [<a href="#rid31">31,32</a>]. The agent used for ALT should be one to which the organism is susceptible, even though the high antibiotic concentrations in ALT may overcome certain mechanisms of resistance. This is further underscored by studies that suggest a decreasing antibiotic concentration gradient across the length of the catheter in ALT, with small quantities of drug diffusing from the distal catheter into the bloodstream [<a href="#rid33">33,34</a>].</p><p>In general, we add heparin to our ALT solutions to help maintain catheter patency; heparin may also facilitate antibiotic penetration into some biofilms by interfering with fibrin formation [<a href="#rid8">8,9</a>]. However, heparin should not be used in ALT solutions in individuals with a history of heparin-induced thrombocytopenia (HIT) or in patients for whom large systemic doses of heparin would be dangerous if the lock solution were inadvertently flushed, such as infants (see  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>). In addition, heparin is incompatible with certain antibiotics  (<a class="graphic graphic_table graphicRef122410" href="/z/d/graphic/122410.html" rel="external">table 2</a>) [<a href="#rid18">18,35</a>]. There are no comparative clinical studies demonstrating that ALT solutions containing heparin are more effective than solutions without heparin.</p><p class="headingAnchor" id="H21997953"><span class="h3">Administration</span><span class="headingEndMark"> — </span>ALT should be used in conjunction with systemic antibiotics. Issues related to selection of systemic antibiotic therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Catheter salvaged'</a>.)</p><p class="headingAnchor" id="H13928516"><span class="h4">Preparation, instillation, and dwell time</span><span class="headingEndMark"> — </span>The catheter lumen fill volume should be determined in order to identify the volume of lock solution needed to fill the lumen but not spill into the systemic circulation. A common method used to determine the fill volume is to flush the line with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, attach a new 5 mL syringe to the catheter, and aspirate slowly until blood appears at the syringe tip; the amount of saline in the syringe is the "fill volume" of lock solution that should be administered to the patient. Notably, as the internal end of the catheter is open, some diffusion of lock solution into the circulation is inevitable and of an unpredictable amount; moreover, there exists the risk for accidental flushing of the lock solution into the systemic circulation.</p><p>Antimicrobial lock solutions should be prepared using aseptic technique under sterile conditions immediately prior to instillation into the catheter lumen by mixing the appropriate solutions in a single syringe. The solutions should be prepared using proper protocols for injection safety [<a href="#rid36">36</a>].</p><p>In general, the catheter should be locked with ALT solution whenever the catheter is not otherwise being used (eg, for infusion of systemic antibiotics, other medications, intravenous fluids, or nutrition). When feasible, alternative intravenous access should be used for administration of agents other than antimicrobial therapy. </p><p>Ideally ALT should be instilled at least once daily. The optimal dwell time is unknown; dwell times may range from hours to days, depending on stability of the lock solution and the amount of time available when the catheter is not in use. Some studies support a minimum dwell time of 8 to 12 hours [<a href="#rid7">7</a>]. In one prospective study including 30 patients, successful catheter salvage was observed with once daily ALT instillation with a dwell time as short as two hours [<a href="#rid37">37</a>]. Given the available data, we favor a minimum ALT dwell time of two hours. </p><p>Maximum dwell times for antibiotic lock solutions (based on their physical and chemical stability) are summarized in the table  (<a class="graphic graphic_table graphicRef122410" href="/z/d/graphic/122410.html" rel="external">table 2</a>). In general, we favor limiting the dwell time to 24 to 48 hours, since antibiotic concentrations in the catheter can fall to subtherapeutic levels over time [<a href="#rid1">1,33</a>].</p><p>For multilumen catheters, instillation of ALT into all lumens is preferred when feasible; it may be necessary to rotate lumens every 12 to 24 hours in order to administer other intravenous fluids or medications. If a significant number of intravenous therapies are needed, the agents should be reviewed for Y-site compatibility to optimize ALT dwell time in the infected catheter; alternatively, administration of intravenous therapies via peripheral vein access could be considered. </p><p>At the end of the dwell time or when the catheter is required for alternate use, the ALT should be withdrawn (not flushed into the vein) and discarded, to avoid systemic exposure to the antimicrobial and/or anticoagulant.</p><p class="headingAnchor" id="H21997765"><span class="h4">Duration of therapy</span><span class="headingEndMark"> — </span>In general, the duration of ALT is the same as the duration of systemic antibiotic therapy, which depends on the organism and other patient factors [<a href="#rid1">1</a>]. Issues related to duration of therapy are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Catheter salvaged'</a>.)</p><p class="headingAnchor" id="H1142618873"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>When adjunctive ALT is used as CRBSI treatment, monitoring of serum levels of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is not required (unless these antibiotics are also being given parenterally) because systemic exposure from lock therapy is minimal and treatment courses are relatively short. </p><p>Issues related to monitoring during management of CRBSI via catheter salvage are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Monitoring and indications for catheter removal'</a>.)</p><p class="headingAnchor" id="H2197427602"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Limited data suggest that ALT is associated with reductions in rates of subsequent catheter removal and complications. Most studies on the efficacy of ALT for adjunctive treatment of CRBSI were small, observational, and/or lacked contemporary controls [<a href="#rid37">37-39</a>]. Furthermore, interpretation of available data is challenging given variability in CRBSI definitions, catheter types, ALT agents, outcomes reported, and duration of follow-up. </p><p>In a 2011 meta-analysis that included eight (one randomized and seven observational)<em> </em>studies and more than 390 patients with CRBSI, catheter replacement was needed less frequently among patients treated with systemic antibiotics plus ALT than among patients with systemic antibiotics alone (10 versus 33 percent; odds ratio 0.20, 95% CI 0.10-0.39) [<a href="#rid39">39</a>]. In a 2016 observational study that included outcomes of 90 patients with CRBSI who were enrolled prospectively and treated with ALT and systemic therapy and then compared with historical controls, the rate of infectious complications (septic thrombophlebitis, deep-seated infection)<em> </em>was lower among the patients treated with ALT than among the control group (0 versus 12 percent) [<a href="#rid37">37</a>]. </p><p>Common contexts for use of ALT include patients with catheters for receiving chemotherapy and <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> [<a href="#rid15">15,24,26,37,38,40-54</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with CRBSI in the setting of solid tumor or hematologic malignancy, available data from small, observational studies suggest that adding ALT to standard systemic antibiotic therapy may increase catheter salvage rates [<a href="#rid26">26,37,48,49</a>]. A retrospective study of 24 hematopoietic stem cell transplant patients with CRBSI found that catheter salvage rates were higher among patients who received ALT plus systemic antibiotics versus systemic therapy alone (86 versus 55 percent) [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In adults requiring <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, small observational studies of ALT have reported catheter salvage rates of 25 to 100 percent [<a href="#rid15">15,50-54</a>]. However, none of the lock solutions contained heparin, and there was substantial variability in antibiotic choice, dwell time, duration of therapy, and use of concomitant systemic antibiotics. A systematic review of CRBSI management in adults receiving home parenteral nutrition reported a higher rate of catheter salvage with ALT plus systemic therapy versus systemic antibiotics alone, but only 1 of the 28 included studies involved direct comparison of these two groups [<a href="#rid55">55</a>].</p><p></p><p>Data on ALT in patients with port-related BSI are limited and reported success rates range from 18 to 100 percent [<a href="#rid44">44-47</a>]. </p><p>Available studies in children are largely limited to retrospective case series [<a href="#rid56">56,57</a>]. In children, host factors may influence the probability of catheter salvage with ALT. In a small series of pediatric oncology patients, younger age was associated with a higher risk of treatment failure during lock therapy [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H13928508"><span class="h3">Adverse effects of ALT as therapy</span><span class="headingEndMark"> — </span>Potential adverse effects of ALT for treatment of CRBSI include systemic toxicity associated with the agents in the lock solution, emergence of antibiotic resistance, and secondary candidemia.</p><p>Potential adverse effects of heparin include risk of bleeding from inadvertent systemic anticoagulation and risk of HIT. Heparin should not be used in ALT for individuals with a history of HIT. The rate of adverse events is likely lower with ALT than with systemic heparin administration since ALT solutions are not flushed, but direct comparative data are not available [<a href="#rid18">18,35</a>]. </p><p>Diffusion of medication from the locked catheter lumen into the systemic circulation can occur [<a href="#rid33">33</a>]. However, no reports of significant toxicity associated with ALT for adjunctive treatment of CRBSI have been described.</p><p>Data on emergence of antibiotic resistance associated with ALT are limited. One retrospective study found no increased risk of resistance when 662 hemodialysis patients treated with systemic antibiotic therapy and ALT were compared to 265 historical controls treated with systemic therapy alone [<a href="#rid59">59</a>]. </p><p>Secondary candidemia has been observed among patients receiving ALT for CRBSI [<a href="#rid15">15,19</a>]. In one prospective study including 79 patients on hemodialysis with CRBSI treated with systemic antibiotic therapy and ALT, treatment failure occurred in 49 percent of cases. Positive surveillance cultures were observed in 15 patients, including nine patients with secondary candidemia [<a href="#rid19">19</a>]. </p><p class="headingAnchor" id="H3138893740"><span class="h2">Limitations of other lock types</span><span class="headingEndMark"> — </span>Given concern that use of antibiotic locks may promote antimicrobial resistance, alternative agents have been evaluated. However, data are too limited to support their routine use. </p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol has been proposed as an alternative lock solution as it is bactericidal and fungicidal against a broad range of microorganisms. However, ethanol locks should not be used routinely for treatment of CRBSI pending further study because available data are limited by small sample sizes and study heterogeneity. In small observational studies (particularly in pediatric populations), ethanol locks have demonstrated comparable efficacy to antibiotic locks [<a href="#rid37">37,60-65</a>].</p><p></p><p class="bulletIndent1">Use of ethanol locks may promote release of polymer components from polyurethane catheters and increase the risk for catheter occlusion or breakage; this is less of a concern with silicone catheters [<a href="#rid66">66-68</a>]. Ethanol is incompatible with heparin; therefore, heparin should never be added to ethanol lock solutions. In addition, ethanol locks should not be used in patients with a history of alcohol use disorder or patients on <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (given the possibility of disulfiram-like reaction).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Taurolidine is a derivative of the amino acid taurine that exhibits antimicrobial properties against gram-positive cocci, Enterobacteriaceae, and <em>Candida</em> species. In a case series of adults with cancer and CRBSI treated with 2% taurolidine locks for five days along with systemic antimicrobials, treatment was successful in 25 of 26 patients, and no adverse events were reported [<a href="#rid69">69</a>]. However, this agent is not widely available, and a paucity of data preclude its routine use at this time. </p><p></p><p>Other proposed lock additives include <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (which may be capable of degrading biofilm matrices) [<a href="#rid70">70,71</a>], ion chelators (such as citrate and ethylenediaminetetraacetic acid) [<a href="#rid7">7,37</a>], and lock solutions containing chelators as well as antimicrobials [<a href="#rid72">72</a>]. Pending further study, there is no role for routine use of these agents.</p><p class="headingAnchor" id="H4202387"><span class="h1">LOCK USE FOR CRBSI PREVENTION</span><span class="headingEndMark"> — </span>Issues related to use of locks for secondary prevention of catheter-related bloodstream infection (CRBSI) in patients with long-term catheters (apart from hemodialysis catheters) and a history of recurrent CRBSI are discussed below. Other issues related to CRBSI prevention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a>.)</p><p>Issues related to locks for prevention of CRBSI in hemodialysis catheters are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">"Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management", section on 'Access, flushing, and catheter locking'</a>.)</p><p class="headingAnchor" id="H2182087080"><span class="h2">Indications</span><span class="headingEndMark"> — </span>We do not routinely use antibiotic locks for prevention of CRBSI. However, for patients with long-term non-hemodialysis catheters and a history of recurrent CRBSI despite adherence to other routine infection prevention measures, we suggest use of antibiotic locks for prevention of CRBSI. This approach is in agreement with the 2011 Infectious Disease Society of America guidelines and the 2014 Society for Healthcare Epidemiology of America guidelines [<a href="#rid73">73,74</a>]. </p><p>Data on the efficacy of antibiotic locks for prevention of CRBSI include randomized trials and meta-analyses [<a href="#rid75">75-81</a>]. In one meta-analysis of 23 randomized trials including more than 2800 patients with indwelling catheters (mostly adults on hemodialysis but also including adult and pediatric oncology patients, critically ill neonates, and patients receiving total <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>), use of antibiotic locks for prevention of CRBSI was associated with a 69 percent relative reduction in rates of CRBSI (absolute risk reduction 0.11 percent; relative risk [RR] 0.31; 95% CI 0.24-0.40) [<a href="#rid79">79</a>]. Among adults and children with cancer, a meta-analysis of six randomized controlled trials reported that antibiotic-heparin locks or flushes reduced the risk of gram-positive CRBSI by 53 percent (95% CI 15-74) compared with heparin locks or flushes alone [<a href="#rid80">80</a>]. These studies were heterogeneous (eg, catheter type, antibiotic and concentration, duration of central venous catheter [CVC] placement, infection definitions were variable), and only two of the studies evaluated lock therapy.</p><p>Ethanol locks are an alternative to antibiotic locks for prevention of CRBSI; data regarding their use are limited. Prophylactic ethanol locks may be considered on a case-by-case basis for patients in certain circumstances as discussed below. (See <a class="local">'Alternative lock solutions'</a> below.)</p><p class="headingAnchor" id="H2759704434"><span class="h2">Antibiotic lock solutions</span></p><p class="headingAnchor" id="H348609793"><span class="h3">Selection and administration</span><span class="headingEndMark"> — </span>The choice of antibiotic lock solution for prevention of CRBSI should be guided by the microbiology of prior CRBSI episodes. </p><p>Antibiotic concentrations for prevention of CRBSI differ from those used for adjunctive treatment of CRBSI: </p><p class="bulletIndent1"><span class="glyph">●</span>For secondary prevention of CRBSI among patients with recurrent infection due to gram-positive organisms, we favor the combination of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (25 mcg/mL) and heparin (10 units/mL); this is the best-studied antibiotic lock solution for prevention [<a href="#rid75">75-77</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For secondary prevention of CRBSI among patients with recurrent infection due to gram-negative organisms, we favor the combination of <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and heparin; the optimal dose is uncertain. Gentamicin (5 mg/mL) and heparin (5000 units/mL) has been used successfully (primarily in patients with hemodialysis catheters); successful prophylactic gentamicin concentrations have ranged from 0.32 to 5 mg/mL [<a href="#rid82">82-85</a>]. In some patients receiving prophylactic high-concentration gentamicin locks, detectable systemic levels of gentamicin have been associated with vestibular symptoms (in the absence of hearing loss) [<a href="#rid85">85</a>]. Alternative agents to gentamicin include cephalosporins (such as <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>) or fluoroquinolones; however, data regarding prophylactic dosing of these agents are limited. </p><p></p><p>As with therapeutic lock therapy, heparin should not be included in prophylactic lock solutions in individuals with a history of heparin-induced thrombocytopenia (HIT) or in individuals for whom large systemic doses of heparin would be dangerous if the lock solution were inadvertently flushed, such as infants. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p>The optimal approach to frequency of administration of lock prophylaxis is uncertain. We favor administration daily or every other day with dwell times of one hour; in small studies, this approach has been associated with reduced rates of CRBSI [<a href="#rid75">75,76</a>]. </p><p>The catheter lumen fill volume should be determined in order to identify the volume of lock solution needed to fill the lumen but not spill into the systemic circulation. One method to determine the fill volume is to flush the line with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, attach a new 5 mL syringe to the catheter, and aspirate slowly until blood appears at the syringe tip; the amount of saline in the syringe is the "fill volume" of lock solution that should be administered to the patient. </p><p>Antimicrobial lock solutions should be prepared using aseptic technique under sterile conditions immediately prior to instillation into the catheter lumen by mixing the appropriate solutions in a single syringe. The solutions should be prepared using proper protocols for injection safety [<a href="#rid36">36</a>].</p><p>For multilumen catheters, instillation of antibiotic lock therapy (ALT) into all lumens is preferred when feasible; it may be necessary to rotate lumens in order to administer other intravenous fluids or medications. </p><p>At the end of the dwell time, the ALT should be withdrawn (not flushed into the vein) and discarded, to avoid systemic exposure to the antimicrobial and/or anticoagulant.</p><p class="headingAnchor" id="H2391448518"><span class="h3">Duration and monitoring</span><span class="headingEndMark"> — </span>The optimal duration for lock prophylaxis is uncertain. For patients with recurrent CRBSI in the setting of malignancy who are receiving myelosuppressive chemotherapy, it may be reasonable to use lock prophylaxis during periods of neutropenia [<a href="#rid75">75</a>]. For other patients, lock prophylaxis may be needed for the duration of catheter retention. </p><p>For patients receiving ALT as prophylaxis, monitoring of serum levels of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is not typically required because systemic exposure from locks is minimal. However, it may be reasonable to periodically monitor levels if a patient experiences symptoms of toxicity, has underlying renal insufficiency or advanced age, or is on concurrent nephrotoxic agents. The rationale for this approach is discussed below. (See <a class="local">'Adverse effects of ALT as prevention'</a> below.) </p><p>Patients receiving aminoglycoside ALT should be educated to report the onset of vestibular symptoms or changes in hearing. If long-term use is anticipated, baseline audiology testing is warranted. </p><p class="headingAnchor" id="H3973155122"><span class="h3">Adverse effects of ALT as prevention</span><span class="headingEndMark"> — </span>Although antimicrobial locks used for CRBSI prevention are used for longer periods of time than when used for treatment, the risk of systemic toxicity from the agents in the lock solution (such as ototoxicity from aminoglycoside locks) remains low. However, detectable <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> levels have been reported in some hemodialysis patients on prophylactic ALT, along with some reports of dizziness (no vertigo or hearing loss were reported) [<a href="#rid85">85</a>]. A case report described sudden hearing loss in a patient receiving <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> locks for prophylaxis, but this case was confounded by the prior use of several courses of systemic amikacin therapy [<a href="#rid17">17</a>]. </p><p>Data on whether prophylactic ALT induces antibiotic resistance are inconclusive [<a href="#rid86">86</a>]. In one meta-analysis including 11 trials and more than 900 patients who received prophylactic ALT, development of antibiotic resistance was documented in one patient [<a href="#rid87">87</a>]. In a subsequent study including more than 1400 patients who received a gentamicin-heparin lock for prevention of CRBSI over a four-year period, 24 episodes of CRBSI due to a gentamicin-resistant organism were observed; outcomes included four deaths, two cases of septic shock requiring intensive care unit admission, and four cases of endocarditis<em> </em>[<a href="#rid88">88</a>]. </p><p>Heparin in prophylactic lock solutions can cause the same adverse effects as heparin in therapeutic lock solutions, namely inadvertent bleeding or HIT. Further information is found above. (See <a class="local">'Adverse effects of ALT as therapy'</a> above.)</p><p class="headingAnchor" id="H2006789760"><span class="h2">Alternative lock solutions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethanol locks</strong> – Data for use of ethanol locks for CRBSI prophylaxis are emerging; this remains an area of ongoing investigation. Prophylactic ethanol locks may be used on a case-by-case basis in patients meeting the following criteria, after considering risks and alternative strategies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with prior CRBSI episodes due to different organisms, for which a single prophylactic antibiotic agent may not be effective.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with prior CRBSI episodes caused by drug-resistant pathogens; in such cases, use of an ethanol lock serves as an alternative to use of broad-spectrum antibiotics. </p><p></p><p class="bulletIndent1">The data informing the benefit of ethanol locks are mixed, with some studies supporting and other studies suggesting no benefit. Data supporting use of ethanol locks for prevention of CRBSI in the setting of malignancy (solid tumor or hematologic malignancy) and <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one trial including 64 adults with hematologic malignancies, patients were randomly assigned to receive a 70% ethanol lock (daily for two hours) or a heparinized <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> lock (control); the rate of CRBSI was lower among the patients who received the ethanol lock (9 versus 37 percent) [<a href="#rid89">89</a>]. The rate of CRBSI in patients in the control arm was higher than rates of CRBSI reported at other centers, raising uncertainty about the relative efficacy of this procedure at institutions with low baseline rates of CRBSI. In a subsequent randomized trial including 85 adults with hematologic malignancies, use of ethanol locks (daily for two hours) or heparinized saline locks was associated with comparable rates of CRBSI (6 versus 4 percent) [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Data on use of ethanol locks for CRBSI prevention among children with cancer are conflicting. In one study including 94 children randomly assigned to CRBSI prevention with ethanol lock or placebo, the rate of CRBSI was similar (43 versus 44 percent; RR 1.0, 95% CI 0.6-1.6) [<a href="#rid91">91</a>]. However, in an earlier randomized trial including more than 300 children with cancer, patients received a 70% ethanol lock (dwell time two hours, administered once weekly to once every six weeks) or heparin; the rate of CRBSI was lower among those who received ethanol locks (0.77 versus 1.46 per 1000 catheter days) [<a href="#rid92">92</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis including four retrospective studies and 53 children receiving <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, use of ethanol lock prophylaxis was associated with an 81 percent reduction in CRBSI relative to heparin locks [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1">Most studies of ethanol locks for prevention of CRBSI have used daily administration of a 70% solution with dwell times of at least two to four hours [<a href="#rid89">89,92,94-96</a>]. Lower concentrations (eg, 30%) may not provide adequate protection against infection and should be avoided [<a href="#rid97">97</a>]. </p><p></p><p class="bulletIndent1">Contraindications to use of ethanol locks (for prevention or treatment) are discussed above. (See <a class="local">'Limitations of other lock types'</a> above.)</p><p></p><p class="bulletIndent1">Adverse effects associated with ethanol lock flushing include nausea, dysgeusia, alcoholic taste, dizziness, and skin flushing [<a href="#rid92">92,98,99</a>]. In addition, use of ethanol locks for prevention of CRBSI has been associated with an increased risk of catheter thrombosis [<a href="#rid66">66,100,101</a>]; in an observational study including seven patients with a single-lumen silicone central line exposed to both heparin lock (in the absence of antibiotic lock) as well as ethanol lock therapy, the number of thrombotic events was 1 and 12 on heparin lock and ethanol lock therapy, respectively (rate 0.46 versus 3.27 per 1000 catheter days) [<a href="#rid101">101</a>]. </p><p></p><p class="bulletIndent1">In some regions, high costs and limited availability of ethanol locks hinder the wide implementation of this practice [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Locks containing chelation agents</strong> – Chelating agents (such as ethylenediaminetetraacetic acid or citrate) have been investigated for the prevention of CRBSI, primarily in hemodialysis patients. The reported efficacy has been conflicting. Potential adverse effects include catheter dysfunction and reduced patency [<a href="#rid72">72,103-105</a>]. Pending further study, there is no role for routine use of these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Taurolidine locks</strong> – Lock solutions containing taurolidine have been associated with reduction in CRBSI incidence; this agent is not available in many countries, including the United States [<a href="#rid106">106-112</a>]. In a systematic review of four trials including 162 adults receiving <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, the cumulative proportion of CRBSI-free patients using taurolidine, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, and heparin after one year was 88, 56, and 14 percent, respectively [<a href="#rid109">109</a>]. In children, a randomized trial of 129 catheters in 112 cancer patients found that the rate of CRBSI was lower with taurolidine locks versus heparin locks (incident rate ratio, 0.26; 95% CI 0.09-0.61) [<a href="#rid106">106</a>]. Data for taurolidine are limited by variability in concentrations, frequency of administration, and dwell times. Adverse effects reported with taurolidine locks include dysgeusia and paresthesias [<a href="#rid106">106,109</a>]. </p><p></p><p class="headingAnchor" id="H2788680414"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117743.html" rel="external">"Society guideline links: Venous access"</a>.)</p><p class="headingAnchor" id="H50341376"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Antibiotic lock therapy (ALT) refers to instillation of a concentrated antibiotic solution into a catheter lumen and allowing the solution to dwell within the catheter for a set period of time with the goal of achieving a drug level high enough to kill bacteria within the biofilm of the catheter. (See <a class="local">'Introduction'</a> above and <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of CRBSI using ALT</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – For patients with catheter-related bloodstream infection (CRBSI) in whom catheter salvage is appropriate, we suggest using ALT in conjunction with systemic antibiotic therapy rather than using systemic antibiotics alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Observational studies suggest that ALT is associated with higher rates of catheter salvage. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent2">Catheter salvage should not be attempted in patients with a condition that warrants catheter removal; indications for catheter removal are described in detail elsewhere  (<a class="graphic graphic_table graphicRef122402" href="/z/d/graphic/122402.html" rel="external">table 1</a>). (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Selecting a catheter management strategy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selection of antimicrobials</strong> – Commonly used antibiotics for ALT solutions include <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>  (<a class="graphic graphic_table graphicRef122410" href="/z/d/graphic/122410.html" rel="external">table 2</a>). (See <a class="local">'Selection'</a> above.) </p><p></p><p class="bulletIndent2">Systemic antibiotics should be given concurrently with ALT; details regarding systemic therapy are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Empiric antibiotic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Directed systemic antibiotic therapy and duration'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dwell time, frequency, and duration</strong> – We favor minimal dwell times of two hours; maximal dwell times depend on the antibiotic used  (<a class="graphic graphic_table graphicRef122410" href="/z/d/graphic/122410.html" rel="external">table 2</a>). Ideally, fresh ALT solution should be instilled at least once daily. ALT is usually continued for the duration of systemic antimicrobial therapy. (See <a class="local">'Preparation, instillation, and dwell time'</a> above and <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring response</strong> – Persistent symptoms or positive blood cultures 72 hours after initiation of appropriate antibiotics are indications of clinical failure. In this situation, the catheter should be removed and evaluation for complications (including suppurative thrombophlebitis, endocarditis, and metastatic foci of infection) should be pursued. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment", section on 'Monitoring and indications for catheter removal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ALT technique</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preparation of ALT solution</strong> – ALT solutions should be prepared immediately prior to installation by mixing the appropriate solutions using aseptic technique under sterile conditions. We suggest adding heparin to ALT solutions unless the patient has a contraindication to heparin  (<a class="graphic graphic_table graphicRef122410" href="/z/d/graphic/122410.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preparation, instillation, and dwell time'</a> above and <a class="local">'Selection'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> – ALT solutions should be administered via a single syringe in a volume sufficient to fill the catheter lumen but not spill into the systemic circulation. (See <a class="local">'Preparation, instillation, and dwell time'</a> above.) </p><p></p><p class="bulletIndent2">At the end of the dwell time or when the catheter needs to be used, the ALT solution should be withdrawn and discarded. It should not be flushed into the vein. (See <a class="local">'Preparation, instillation, and dwell time'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of CRBSI using ALT</strong> – We do not routinely use ALT for prevention of CRBSI. However, we suggest preventative ALT (without systemic antibiotics) for patients who have recurrent CRBSI despite adherence to proper infection prevention measures in whom catheter salvage is preferred (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Antibiotic selection depends on the causative organisms of prior CRBSI episodes. (See <a class="local">'Lock use for CRBSI prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – These appear to be rare and include systemic toxicity associated with the agents in the lock solution, emergence of antibiotic resistance, and secondary candidemia. (See <a class="local">'Adverse effects of ALT as therapy'</a> above and <a class="local">'Adverse effects of ALT as prevention'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</a></li><li><a class="nounderline abstract_t">Raad I, Davis S, Khan A, et al. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 1992; 13:215.</a></li><li><a class="nounderline abstract_t">Gaillard JL, Merlino R, Pajot N, et al. Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci. JPEN J Parenter Enteral Nutr 1990; 14:593.</a></li><li><a class="nounderline abstract_t">Pascual A, Ramirez de Arellano E, Martínez Martínez L, Perea EJ. Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis. J Hosp Infect 1993; 24:211.</a></li><li><a class="nounderline abstract_t">Raad I, Costerton W, Sabharwal U, et al. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168:400.</a></li><li><a class="nounderline abstract_t">Carratalà J. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. Clin Microbiol Infect 2002; 8:282.</a></li><li><a class="nounderline abstract_t">Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. Infect Drug Resist 2014; 7:343.</a></li><li><a class="nounderline abstract_t">von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 2005; 65:179.</a></li><li><a class="nounderline abstract_t">Kim EY, Saunders P, Yousefzadeh N. Usefulness of anti-infective lock solutions for catheter-related bloodstream infections. Mt Sinai J Med 2010; 77:549.</a></li><li><a class="nounderline abstract_t">Shanks RM, Donegan NP, Graber ML, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73:4596.</a></li><li><a class="nounderline abstract_t">Shanks RM, Sargent JL, Martinez RM, et al. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21:2247.</a></li><li><a class="nounderline abstract_t">Sauer K, Steczko J, Ash SR. Effect of a solution containing citrate/Methylene Blue/parabens on Staphylococcus aureus bacteria and biofilm, and comparison with various heparin solutions. J Antimicrob Chemother 2009; 63:937.</a></li><li><a class="nounderline abstract_t">Mishra S, Horswill AR. Heparin Mimics Extracellular DNA in Binding to Cell Surface-Localized Proteins and Promoting Staphylococcus aureus Biofilm Formation. mSphere 2017; 2.</a></li><li><a class="nounderline abstract_t">Luther MK, Mermel LA, LaPlante KL. Comparison of linezolid and vancomycin lock solutions with and without heparin against biofilm-producing bacteria. Am J Health Syst Pharm 2017; 74:e193.</a></li><li><a class="nounderline abstract_t">Messing B, Peitra-Cohen S, Debure A, et al. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988; 12:185.</a></li><li><a class="nounderline abstract_t">Messing B. Catheter-sepsis during home parenteral nutrition: use of the antibiotic-lock technique. Nutrition 1998; 14:466.</a></li><li><a class="nounderline abstract_t">Saxena AK, Panhotra BR, Naguib M. Sudden irreversible sensory-neural hearing loss in a patient with diabetes receiving amikacin as an antibiotic-heparin lock. Pharmacotherapy 2002; 22:105.</a></li><li><a class="nounderline abstract_t">Karaaslan H, Peyronnet P, Benevent D, et al. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant 2001; 16:2072.</a></li><li><a class="nounderline abstract_t">Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136.</a></li><li><a class="nounderline abstract_t">Bookstaver PB, Williamson JC, Tucker BK, et al. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann Pharmacother 2009; 43:210.</a></li><li><a class="nounderline abstract_t">Vercaigne LM, Sitar DS, Penner SB, et al. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy 2000; 20:394.</a></li><li><a class="nounderline abstract_t">Vercaigne LM, Zelenitsky SA, Findlay I, et al. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother 2002; 49:693.</a></li><li><a class="nounderline abstract_t">LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22:2239.</a></li><li><a class="nounderline abstract_t">Tatarelli P, Parisini A, Del Bono V, et al. Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter. Infection 2015; 43:107.</a></li><li><a class="nounderline abstract_t">Yen HW, Yang WC, Tarng DC, et al. Daptomycin antibiotic lock therapy for hemodialysis patients with Gram-positive bloodstream infections following use of tunneled, cuffed hemodialysis catheters: retrospective single center analysis. Hemodial Int 2016; 20:315.</a></li><li><a class="nounderline abstract_t">Vassallo M, Genillier PL, Dunais B, et al. Short-course daptomycin lock and systemic therapy for catheter-related bloodstream infections: a retrospective cohort study in cancer patients with surgically implanted devices. J Chemother 2017; 29:232.</a></li><li><a class="nounderline abstract_t">Hogan S, Zapotoczna M, Stevens NT, et al. In Vitro Approach for Identification of the Most Effective Agents for Antimicrobial Lock Therapy in the Treatment of Intravascular Catheter-Related Infections Caused by Staphylococcus aureus. Antimicrob Agents Chemother 2016; 60:2923.</a></li><li><a class="nounderline abstract_t">Anthony TU, Rubin LG. Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports). Antimicrob Agents Chemother 1999; 43:2074.</a></li><li><a class="nounderline abstract_t">Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003; 51:849.</a></li><li><a class="nounderline abstract_t">Robinson JL, Tawfik G, Saxinger L, et al. Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy. J Antimicrob Chemother 2005; 56:951.</a></li><li><a class="nounderline abstract_t">Henrickson KJ, Powell KR, Schwartz CL. A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities. J Infect Dis 1988; 157:600.</a></li><li><a class="nounderline abstract_t">Henrickson KJ, Dunne WM Jr. Modification of central venous catheter flush solution improves in vitro antimicrobial activity. J Infect Dis 1992; 166:944.</a></li><li><a class="nounderline abstract_t">Soriano A, Bregada E, Marqués JM, et al. Decreasing gradient of antibiotic concentration in the lumen of catheters locked with vancomycin. Eur J Clin Microbiol Infect Dis 2007; 26:659.</a></li><li><a class="nounderline abstract_t">Labriola L, Pochet JM. Any use for alternative lock solutions in the prevention of catheter-related blood stream infections? J Vasc Access 2017; 18:34.</a></li><li><a class="nounderline abstract_t">Yevzlin AS, Sanchez RJ, Hiatt JG, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial 2007; 20:351.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Injection safety. https://www.cdc.gov/injectionsafety/ (Accessed on September 05, 2019).</li><li><a class="nounderline abstract_t">Raad I, Chaftari AM, Zakhour R, et al. Successful Salvage of Central Venous Catheters in Patients with Catheter-Related or Central Line-Associated Bloodstream Infections by Using a Catheter Lock Solution Consisting of Minocycline, EDTA, and 25% Ethanol. Antimicrob Agents Chemother 2016; 60:3426.</a></li><li><a class="nounderline abstract_t">Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 2005; 55:90.</a></li><li><a class="nounderline abstract_t">O'Horo JC, Silva GL, Safdar N. Anti-infective locks for treatment of central line-associated bloodstream infection: a systematic review and meta-analysis. Am J Nephrol 2011; 34:415.</a></li><li><a class="nounderline abstract_t">Boorgu R, Dubrow AJ, Levin NW, et al. Adjunctive antibiotic/anticoagulant lock therapy in the treatment of bacteremia associated with the use of a subcutaneously implanted hemodialysis access device. ASAIO J 2000; 46:767.</a></li><li><a class="nounderline abstract_t">Viale P, Pagani L, Petrosillo N, et al. Antibiotic lock-technique for the treatment of catheter-related bloodstream infections. J Chemother 2003; 15:152.</a></li><li><a class="nounderline abstract_t">Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 2006; 57:1172.</a></li><li><a class="nounderline abstract_t">Fortún J, Grill F, Martín-Dávila P, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 2006; 58:816.</a></li><li><a class="nounderline abstract_t">Megged O, Shalit I, Yaniv I, et al. Outcome of antibiotic lock technique for persistent central venous catheter-associated coagulase-negative Staphylococcus bacteremia in children. Eur J Clin Microbiol Infect Dis 2010; 29:157.</a></li><li><a class="nounderline abstract_t">Longuet P, Douard MC, Arlet G, et al. Venous access port--related bacteremia in patients with acquired immunodeficiency syndrome or cancer: the reservoir as a diagnostic and therapeutic tool. Clin Infect Dis 2001; 32:1776.</a></li><li><a class="nounderline abstract_t">Del Pozo JL, Alonso M, Serrera A, et al. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. Diagn Microbiol Infect Dis 2009; 63:208.</a></li><li><a class="nounderline abstract_t">Del Pozo JL, García Cenoz M, Hernáez S, et al. Effectiveness of teicoplanin versus vancomycin lock therapy in the treatment of port-related coagulase-negative staphylococci bacteraemia: a prospective case-series analysis. Int J Antimicrob Agents 2009; 34:482.</a></li><li><a class="nounderline abstract_t">Sánchez-Muñoz A, Aguado JM, López-Martín A, et al. Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. Eur J Clin Microbiol Infect Dis 2005; 24:291.</a></li><li><a class="nounderline abstract_t">Zanwar S, Jain P, Gokarn A, et al. Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection. Transpl Infect Dis 2019; 21:e13017.</a></li><li><a class="nounderline abstract_t">Messing B, Man F, Colimon R, et al. Antibiotic-lock technique is an effective treatment of bacterial catheter-related sepsis during parenteral nutrition. Clin Nutr 1990; 9:220.</a></li><li><a class="nounderline abstract_t">Williams N, Carlson GL, Scott NA, Irving MH. Incidence and management of catheter-related sepsis in patients receiving home parenteral nutrition. Br J Surg 1994; 81:392.</a></li><li><a class="nounderline abstract_t">Krzywda EA, Andris DA, Edmiston CE Jr, Quebbeman EJ. Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect Control Hosp Epidemiol 1995; 16:596.</a></li><li><a class="nounderline abstract_t">Benoit JL, Carandang G, Sitrin M, Arnow PM. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis 1995; 21:1286.</a></li><li><a class="nounderline abstract_t">Reimund JM, Arondel Y, Finck G, et al. Catheter-related infection in patients on home parenteral nutrition: results of a prospective survey. Clin Nutr 2002; 21:33.</a></li><li><a class="nounderline abstract_t">Gompelman M, Paus C, Bond A, et al. Comparing success rates in central venous catheter salvage for catheter-related bloodstream infections in adult patients on home parenteral nutrition: a systematic review and meta-analysis. Am J Clin Nutr 2021; 114:1173.</a></li><li><a class="nounderline abstract_t">Wolf J, Allison KJ, Tang L, et al. No evidence of benefit from antibiotic lock therapy in pediatric oncology patients with central line-related bloodstream infection: results of a retrospective matched cohort study and review of the literature. Pediatr Blood Cancer 2014; 61:1811.</a></li><li><a class="nounderline abstract_t">Schoot RA, van Dalen EC, van Ommen CH, van de Wetering MD. Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer. Cochrane Database Syst Rev 2013; :CD008975.</a></li><li><a class="nounderline abstract_t">Asrak HK, Belet N, Tüfekçi Ö, et al. Investigating the risk factors for antibiotic lock therapy failure in pediatric cancer: a single center retrospective analysis. Turk J Pediatr 2021; 63:86.</a></li><li><a class="nounderline abstract_t">Dixon JJ, Steele M, Makanjuola AD. Anti-microbial locks increase the prevalence of Staphylococcus aureus and antibiotic-resistant Enterobacter: observational retrospective cohort study. Nephrol Dial Transplant 2012; 27:3575.</a></li><li><a class="nounderline abstract_t">Onland W, Shin CE, Fustar S, et al. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med 2006; 160:1049.</a></li><li><a class="nounderline abstract_t">Broom J, Woods M, Allworth A, et al. Ethanol lock therapy to treat tunnelled central venous catheter-associated blood stream infections: results from a prospective trial. Scand J Infect Dis 2008; 40:399.</a></li><li><a class="nounderline abstract_t">Dannenberg C, Bierbach U, Rothe A, et al. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol 2003; 25:616.</a></li><li><a class="nounderline abstract_t">Valentine KM. Ethanol lock therapy for catheter-associated blood stream infections in a pediatric intensive care unit. Pediatr Crit Care Med 2011; 12:e292.</a></li><li><a class="nounderline abstract_t">McGrath E, Du W, Rajpurkar M. Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter-Associated Bloodstream Infection: Impact on Length of Stay, Cost, and Catheter Salvage. Clin Pediatr (Phila) 2018; 57:285.</a></li><li><a class="nounderline abstract_t">Blackwood RA, Issa M, Klein K, et al. Ethanol Lock Therapy for the Treatment of Intravenous Catheter Infections That Have Failed Standard Treatment. J Pediatric Infect Dis Soc 2017; 6:94.</a></li><li><a class="nounderline abstract_t">Mermel LA, Alang N. Adverse effects associated with ethanol catheter lock solutions: a systematic review. J Antimicrob Chemother 2014; 69:2611.</a></li><li><a class="nounderline abstract_t">Mokha JS, Davidovics ZH, Samela K, Emerick K. Effects of Ethanol Lock Therapy on Central Line Infections and Mechanical Problems in Children With Intestinal Failure. JPEN J Parenter Enteral Nutr 2017; 41:625.</a></li><li><a class="nounderline abstract_t">Meckmongkol TT, Costanzo C, Ciullo S, et al. Hidden morbidity of ethanol lock therapy. Pediatr Surg Int 2018; 34:71.</a></li><li><a class="nounderline abstract_t">Brescia F, Pittiruti M, Scoppettuolo G, et al. Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients. J Vasc Access 2023; 24:87.</a></li><li><a class="nounderline abstract_t">Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother 2007; 51:1556.</a></li><li><a class="nounderline abstract_t">Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia. Infect Control Hosp Epidemiol 2008; 29:894.</a></li><li><a class="nounderline abstract_t">Chaftari AM, Viola GM, Rosenblatt J, et al. Advances in the prevention and management of central-line-associated bloodstream infections: The role of chelator-based catheter locks. Infect Control Hosp Epidemiol 2019; 40:1036.</a></li><li><a class="nounderline abstract_t">O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:e162.</a></li><li><a class="nounderline abstract_t">Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol 2022; 43:553.</a></li><li><a class="nounderline abstract_t">Carratalà J, Niubó J, Fernández-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother 1999; 43:2200.</a></li><li><a class="nounderline abstract_t">Garland JS, Alex CP, Henrickson KJ, et al. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. Pediatrics 2005; 116:e198.</a></li><li><a class="nounderline abstract_t">Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006; 43:474.</a></li><li><a class="nounderline abstract_t">Snaterse M, Rüger W, Scholte Op Reimer WJ, Lucas C. Antibiotic-based catheter lock solutions for prevention of catheter-related bloodstream infection: a systematic review of randomised controlled trials. J Hosp Infect 2010; 75:1.</a></li><li><a class="nounderline abstract_t">Zacharioudakis IM, Zervou FN, Arvanitis M, et al. Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 59:1741.</a></li><li><a class="nounderline abstract_t">van den Bosch CH, van Woensel J, van de Wetering MD. Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer. Cochrane Database Syst Rev 2021; 10:CD003295.</a></li><li><a class="nounderline abstract_t">van den Bosch CH, Jeremiasse B, van der Bruggen JT, et al. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis. J Hosp Infect 2022; 123:143.</a></li><li><a class="nounderline abstract_t">Moore CL, Besarab A, Ajluni M, et al. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients. Clin J Am Soc Nephrol 2014; 9:1232.</a></li><li><a class="nounderline abstract_t">Silva TN, Mendes ML, Abrão JM, et al. Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin. Int Urol Nephrol 2013; 45:1405.</a></li><li><a class="nounderline abstract_t">Zhang P, Yuan J, Tan H, et al. Successful prevention of cuffed hemodialysis catheter-related infection using an antibiotic lock technique by strictly catheter-restricted antibiotic lock solution method. Blood Purif 2009; 27:206.</a></li><li><a class="nounderline abstract_t">Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13:2133.</a></li><li><a class="nounderline abstract_t">Abbas SA, Haloob IA, Taylor SL, et al. Effect of antimicrobial locks for tunneled hemodialysis catheters on bloodstream infection and bacterial resistance: a quality improvement report. Am J Kidney Dis 2009; 53:492.</a></li><li><a class="nounderline abstract_t">Yahav D, Rozen-Zvi B, Gafter-Gvili A, et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 2008; 47:83.</a></li><li><a class="nounderline abstract_t">Landry DL, Braden GL, Gobeille SL, et al. Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 2010; 5:1799.</a></li><li><a class="nounderline abstract_t">Sanders J, Pithie A, Ganly P, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother 2008; 62:809.</a></li><li><a class="nounderline abstract_t">Worth LJ, Slavin MA, Heath S, et al. Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices. J Hosp Infect 2014; 88:48.</a></li><li><a class="nounderline abstract_t">Wolf J, Connell TG, Allison KJ, et al. Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infect Dis 2018; 18:854.</a></li><li><a class="nounderline abstract_t">Schoot RA, van Ommen CH, Stijnen T, et al. Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: A randomised controlled multi-centre trial. Eur J Cancer 2015; 51:2031.</a></li><li><a class="nounderline abstract_t">Oliveira C, Nasr A, Brindle M, Wales PW. Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics 2012; 129:318.</a></li><li><a class="nounderline abstract_t">Mouw E, Chessman K, Lesher A, Tagge E. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. J Pediatr Surg 2008; 43:1025.</a></li><li><a class="nounderline abstract_t">Jones BA, Hull MA, Richardson DS, et al. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. J Pediatr Surg 2010; 45:1287.</a></li><li><a class="nounderline abstract_t">Cober MP, Kovacevich DS, Teitelbaum DH. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure. JPEN J Parenter Enteral Nutr 2011; 35:67.</a></li><li><a class="nounderline abstract_t">Mohandas A, Isava-Quintero A, Duro D. Thirty percent ethanol locks ineffective in preventing central line-associated bloodstream infection in pediatric intestinal rehabilitation patients. JPEN J Parenter Enteral Nutr 2021; 45:1376.</a></li><li><a class="nounderline abstract_t">Opilla MT, Kirby DF, Edmond MB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr 2007; 31:302.</a></li><li><a class="nounderline abstract_t">Maiefski M, Rupp ME, Hermsen ED. Ethanol lock technique: review of the literature. Infect Control Hosp Epidemiol 2009; 30:1096.</a></li><li><a class="nounderline abstract_t">Wong T, Clifford V, McCallum Z, et al. Central venous catheter thrombosis associated with 70% ethanol locks in pediatric intestinal failure patients on home parenteral nutrition: a case series. JPEN J Parenter Enteral Nutr 2012; 36:358.</a></li><li><a class="nounderline abstract_t">Abu-El-Haija M, Schultz J, Rahhal RM. Effects of 70% ethanol locks on rates of central line infection, thrombosis, breakage, and replacement in pediatric intestinal failure. J Pediatr Gastroenterol Nutr 2014; 58:703.</a></li><li><a class="nounderline abstract_t">Raghu VK, Mezoff EA, Cole CR, et al. Cost-effectiveness of ethanol lock prophylaxis to prevent central line-associated bloodstream infections in children with intestinal failure in the United States. JPEN J Parenter Enteral Nutr 2022; 46:324.</a></li><li><a class="nounderline abstract_t">Quenot JP, Helms J, Bourredjem A, et al. Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial. Ann Intensive Care 2019; 9:75.</a></li><li><a class="nounderline abstract_t">Zhao Y, Li Z, Zhang L, et al. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis 2014; 63:479.</a></li><li><a class="nounderline abstract_t">Parienti JJ, Deryckère S, Mégarbane B, et al. Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patients. Antimicrob Agents Chemother 2014; 58:5666.</a></li><li><a class="nounderline abstract_t">Handrup MM, Møller JK, Schrøder H. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Pediatr Blood Cancer 2013; 60:1292.</a></li><li><a class="nounderline abstract_t">Chu HP, Brind J, Tomar R, Hill S. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock. J Pediatr Gastroenterol Nutr 2012; 55:403.</a></li><li><a class="nounderline abstract_t">Gudiol C, Nicolae S, Royo-Cebrecos C, et al. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT). Trials 2018; 19:264.</a></li><li><a class="nounderline abstract_t">Wouters Y, Causevic E, Klek S, et al. Use of Catheter Lock Solutions in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Individual-Patient Data Meta-Analysis. JPEN J Parenter Enteral Nutr 2020; 44:1198.</a></li><li><a class="nounderline abstract_t">Chong CY, Ong RY, Seah VX, et al. Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates. J Paediatr Child Health 2020; 56:123.</a></li><li><a class="nounderline abstract_t">Klek S, Szczepanek K, Hermanowicz A, Galas A. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial. JPEN J Parenter Enteral Nutr 2015; 39:331.</a></li><li><a class="nounderline abstract_t">Strauss J, Boctor DL, Silverman JA, Casey L. Mechanical Complications in Central Lines Using Taurolidine Versus Ethanol Lock Therapy in Children With Intestinal Failure. J Pediatr Gastroenterol Nutr 2022; 74:776.</a></li></ol></div><div id="topicVersionRevision">Topic 13982 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19489710" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593102" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2273532" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8104211" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335977" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047405" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The antibiotic-lock technique for therapy of 'highly needed' infected catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25548523" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotic lock therapy: review of technique and logistical challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15631541" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Infections associated with medical devices: pathogenesis, management and prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20960556" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Usefulness of anti-infective lock solutions for catheter-related bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040971" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Heparin stimulates Staphylococcus aureus biofilm formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16627606" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282330" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of a solution containing citrate/Methylene Blue/parabens on Staphylococcus aureus bacteria and biofilm, and comparison with various heparin solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28656173" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Heparin Mimics Extracellular DNA in Binding to Cell Surface-Localized Proteins and Promoting Staphylococcus aureus Biofilm Formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28438824" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of linezolid and vancomycin lock solutions with and without heparin against biofilm-producing bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3129594" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9614314" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Catheter-sepsis during home parenteral nutrition: use of the antibiotic-lock technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794420" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sudden irreversible sensory-neural hearing loss in a patient with diabetes receiving amikacin as an antibiotic-heparin lock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572899" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849468" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19193593" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10772369" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11909847" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403700" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25112453" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26549513" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Daptomycin antibiotic lock therapy for hemodialysis patients with Gram-positive bloodstream infections following use of tunneled, cuffed hemodialysis catheters: retrospective single center analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28120698" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Short-course daptomycin lock and systemic therapy for catheter-related bloodstream infections: a retrospective cohort study in cancer patients with surgically implanted devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26926633" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : In Vitro Approach for Identification of the Most Effective Agents for Antimicrobial Lock Therapy in the Treatment of Intravascular Catheter-Related Infections Caused by Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428941" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654743" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16155063" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3343531" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1527437" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Modification of central venous catheter flush solution improves in vitro antimicrobial activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17629756" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Decreasing gradient of antibiotic concentration in the lumen of catheters locked with vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28297055" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Any use for alternative lock solutions in the prevention of catheter-related blood stream infections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635828" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635828" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001822" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful Salvage of Central Venous Catheters in Patients with Catheter-Related or Central Line-Associated Bloodstream Infections by Using a Catheter Lock Solution Consisting of Minocycline, EDTA, and 25% Ethanol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15574481" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21934302" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Anti-infective locks for treatment of central line-associated bloodstream infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110278" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adjunctive antibiotic/anticoagulant lock therapy in the treatment of bacteremia associated with the use of a subcutaneously implanted hemodialysis access device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12797393" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antibiotic lock-technique for the treatment of catheter-related bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16597634" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899468" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911207" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Outcome of antibiotic lock technique for persistent central venous catheter-associated coagulase-negative Staphylococcus bacteremia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11360220" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Venous access port--related bacteremia in patients with acquired immunodeficiency syndrome or cancer: the reservoir as a diagnostic and therapeutic tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026506" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19713086" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effectiveness of teicoplanin versus vancomycin lock therapy in the treatment of port-related coagulase-negative staphylococci bacteraemia: a prospective case-series analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902539" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30369006" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837359" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antibiotic-lock technique is an effective treatment of bacterial catheter-related sepsis during parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8173909" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Incidence and management of catheter-related sepsis in patients receiving home parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568206" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of Hickman catheter sepsis using antibiotic lock technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589156" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884010" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Catheter-related infection in patients on home parenteral nutrition: results of a prospective survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34038951" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparing success rates in central venous catheter salvage for catheter-related bloodstream infections in adult patients on home parenteral nutrition: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24923808" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : No evidence of benefit from antibiotic lock therapy in pediatric oncology patients with central line-related bloodstream infection: results of a retrospective matched cohort study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799867" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33686830" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Investigating the risk factors for antibiotic lock therapy failure in pediatric cancer: a single center retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513704" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Anti-microbial locks increase the prevalence of Staphylococcus aureus and antibiotic-resistant Enterobacter: observational retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018464" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18418801" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ethanol lock therapy to treat tunnelled central venous catheter-associated blood stream infections: results from a prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902914" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21499184" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ethanol lock therapy for catheter-associated blood stream infections in a pediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28664750" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter-Associated Bloodstream Infection: Impact on Length of Stay, Cost, and Catheter Salvage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26501466" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ethanol Lock Therapy for the Treatment of Intravenous Catheter Infections That Have Failed Standard Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891431" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Adverse effects associated with ethanol catheter lock solutions: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826261" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of Ethanol Lock Therapy on Central Line Infections and Mechanical Problems in Children With Intestinal Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29039051" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hidden morbidity of ethanol lock therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34148394" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17220399" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18643743" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31230604" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Advances in the prevention and management of central-line-associated bloodstream infections: The role of chelator-based catheter locks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460264" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Guidelines for the prevention of intravascular catheter-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35437133" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471564" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15995005" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16838237" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20227787" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Antibiotic-based catheter lock solutions for prevention of catheter-related bloodstream infection: a systematic review of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25156111" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34617602" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34767871" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24970874" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23269457" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19176949" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Successful prevention of cuffed hemodialysis catheter-related infection using an antibiotic lock technique by strictly catheter-restricted antibiotic lock solution method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12138146" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19150156" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of antimicrobial locks for tunneled hemodialysis catheters on bloodstream infection and bacterial resistance: a quality improvement report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18498236" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595689" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18621987" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063013" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29884572" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26188849" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: A randomised controlled multi-centre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232307" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558177" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620333" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20959638" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939194" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Thirty percent ethanol locks ineffective in preventing central line-associated bloodstream infection in pediatric intestinal rehabilitation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595439" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19803767" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ethanol lock technique: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975670" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Central venous catheter thrombosis associated with 70% ethanol locks in pediatric intestinal failure patients on home parenteral nutrition: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590214" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Effects of 70% ethanol locks on rates of central line infection, thrombosis, breakage, and replacement in pediatric intestinal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33908050" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cost-effectiveness of ethanol lock prophylaxis to prevent central line-associated bloodstream infections in children with intestinal failure in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31264073" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24125729" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982071" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23417891" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595973" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29720244" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985068" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Use of Catheter Lock Solutions in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Individual-Patient Data Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145505" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24604029" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35213858" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Mechanical Complications in Central Lines Using Taurolidine Versus Ethanol Lock Therapy in Children With Intestinal Failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
